In contrast to PD-L1, one could postulate a direct, broad effect of JAK2 alterations on TME, and a pivotal role of JAK2 in cancer cell sensitivity to IFN-γ, impaired T-cell sensitivity, and evasion (35), by modulating the degree of PD-L1 expression and antigen presentation upon IFN-γ release (36), further augmenting or dampening immune response. The gene discussed is IFNG; the disease is cancer.